HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SB-239063AN

p38 MAPK inhibitor; different than SB-239063

Also Known As:

1-(1,3-dihydroxyprop-2-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl)imidazole

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - SB-239063AN: 2
  - Pyrimidines: 510
    - SB-239063AN: 2

Experts

1.	Behm, David J: 2 articles (04/2005 - 12/2003)
2.	Eybye, Marianne E: 2 articles (04/2005 - 12/2003)
3.	Olzinski, Alan R: 2 articles (04/2005 - 12/2003)
4.	Willette, Robert N: 2 articles (04/2005 - 12/2003)
5.	Bentley, Ross: 1 article (04/2005)
6.	Coatney, Robert W: 1 article (04/2005)
7.	Frazier, Kendall S: 1 article (04/2005)
8.	Maniscalco, Kristeen: 1 article (04/2005)
9.	McCafferty, Tara A: 1 article (04/2005)
10.	Milliner, Chavon M: 1 article (04/2005)

Related Diseases

1.	Proteinuria 04/01/2005 - "Treatment with SB-239063AN delayed the onset of proteinuria and albuminuria. "
2.	Hypertrophy 04/01/2005 - "SB-239063AN treatment also significantly reduced l-NAME-induced interstitial fibrosis in the kidney and restrictive concentric hypertrophy in the left ventricle (end-diastolic volume 0.24+/-0.05 vs. 0.41+/-0.05 ml; p<0.05). "
3.	Hypertension (High Blood Pressure) 12/01/2003 - "100 mg/kg/day) with SB-239063AN inhibited the SFD diet-induced hypertension. "
4.	Fibrosis (Cirrhosis) 04/01/2005 - "SB-239063AN treatment also significantly reduced l-NAME-induced interstitial fibrosis in the kidney and restrictive concentric hypertrophy in the left ventricle (end-diastolic volume 0.24+/-0.05 vs. 0.41+/-0.05 ml; p<0.05). "
5.	Albuminuria 04/01/2005 - "Treatment with SB-239063AN delayed the onset of proteinuria and albuminuria. "

Related Drugs and Biologics

1.	NG-Nitroarginine Methyl Ester (L-NAME)